Mabwell's Innovative CDH17-targeting ADC 7MW4911 Gains Regulatory Approval for Clinical Trials Mabwell has received IND clearance for its CDH17-targeting ADC 7MW4911 from China's NMPA, aiming for clinical studies in advancing gastrointestinal cancers.

Mabwell's Innovative CDH17-targeting ADC 7MW4911 Gains Regulatory Approval for Clinical Trials #China #Shanghai #ADC #Mabwell #CDH17

Mabwell's Innovative CDH17-Targeting ADC Gains FDA IND Approval Mabwell has received IND clearance from the FDA for its innovative CDH17-targeting ADC 7MW4911, set to enter clinical trials for advanced gastrointestinal cancers.

Mabwell's Innovative CDH17-Targeting ADC Gains FDA IND Approval #Mabwell #CDH17 #7MW4911

Mabwell's CDH17-Targeting ADC 7MW4911 Gains IND Approval from NMPA and FDA Mabwell's innovative ADC, 7MW4911, targeting CDH17, has received IND application acceptance from both the NMPA and FDA, marking a significant step in cancer treatment.

Mabwell's CDH17-Targeting ADC 7MW4911 Gains IND Approval from NMPA and FDA #China #Shanghai #Mabwell #CDH17 #7MW4911